FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099690070> ?p ?o ?g. }

• W3099690070 abstract "Background Cancer immunotherapies have been very successful in recent times; however, they benefit only a subset of patients and have varying response rates across tumor types. Conversely, conventional chemotherapies are effective in a large group of patients, but have limited dosing capabilities, lack specificity, and often result in systemic adverse events. Here, we present SQ3370, a novel approach that activates doxorubicin (Dox) at the tumor site while avoiding systemic toxicities commonly associated with the therapy, and also potentially activates an immune response against tumors. SQ3370 is based on a local intratumoral injection of a prodrug-capturing biomaterial (SQL70) followed by 5 daily systemic infusions of an attenuated form of Dox (SQP33). Mutually-reactive click chemistry groups in the 2 components allow the capture and release of active Dox at the tumor site. While conventional Dox is known to induce immune activation 1 and enhance tumor responsiveness to checkpoint inhibitors, 2 its benefit is limited by cumulative dose cardiotoxicity. We safely administered SQ3370 in dogs at 8.95-times the veterinary clinical dose of Dox with minimal side effects including cardiotoxicity and immunosuppression. In syngeneic mouse models, SQ3370 improved overall survival and induced a robust anti-tumor response against the biomaterial-injected lesion compared to conventional Dox. Surprisingly, SQ3370 also induced regression of the non-injected tumor and enhanced T-cell infiltration in both injected and noninjected tumors. We hypothesize that activating Dox at a local site with SQ3370 promotes activation of the native immune system against the tumor. Thus, SQ3370 represents a new therapeutic modality to treat solid tumors by using a drug with known efficacy, Dox, and expanding its therapeutic window. SQ3370 could potentially also benefit patients with widely disseminated or micro-metastatic lesions. Methods SQ3370-001 ( NCT04106492 ), the first-in-human Phase 1 study, is currently open in the United States and Australia to treat patients with advanced solid tumors. SQ3370-001 is enrolling patients ≥ 18 years of age with an injectable local or metastatic lesion, for which published data indicates responsiveness to anthracyclines. Patients must be relapsed or refractory following standard of care therapy and must not have received more than 225 mg/m 2 of Dox (or equivalent anthracycline). Each cycle will be for 21 days with no limit on total cycles. Primary objectives include determining the safety, tolerability, and recommended Phase 2 dose. Additional objectives include assessment of the pharmacokinetic profile, preliminary efficacy per RECIST 1.1, and immune response. Results N/A Conclusions N/A Acknowledgements The authors would like to thank the National Institutes of Health (NIH), the National Science Foundation (NSF), and Y Combinator. Ethics Approval This study was approved by:1. The Institutional Review Board (IRB) of Stanford University; eProtocol Number: 54928.2. The IRB of The University of Texas MD Anderson Cancer Center; IRB ID Number: 2020-0185_MOD001.3. Western IRB, on behalf of The Angeles Clinic and Research Institute and Henry Ford Health System IRB Office; IRB Tracking Number: 20200758.4. Bellberry Limited Human Research Ethics Committee, on behalf of Royal North Shore Hospital and Chris O’Brien Lifehouse; Application Number: 2019-10-848. References Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011;71:4809–4820. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74–88." @default.
• W3099690070 created "2020-11-23" @default.
• W3099690070 creator A5001300397 @default.
• W3099690070 creator A5008969784 @default.
• W3099690070 creator A5013174582 @default.
• W3099690070 creator A5014129738 @default.
• W3099690070 creator A5026093243 @default.
• W3099690070 creator A5028047400 @default.
• W3099690070 creator A5034845901 @default.
• W3099690070 creator A5043675371 @default.
• W3099690070 creator A5051920004 @default.
• W3099690070 creator A5053058346 @default.
• W3099690070 creator A5060528631 @default.
• W3099690070 creator A5086182958 @default.
• W3099690070 date "2020-11-01" @default.
• W3099690070 modified "2023-09-23" @default.
• W3099690070 title "416 SQ3370–001 is a multi-center open-label phase I dose-escalation study to test a novel intratumoral and systemic approach to treat advanced solid tumors" @default.
• W3099690070 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0416" @default.
• W3099690070 hasPublicationYear "2020" @default.
• W3099690070 type Work @default.
• W3099690070 sameAs 3099690070 @default.
• W3099690070 citedByCount "0" @default.
• W3099690070 crossrefType "journal-article" @default.
• W3099690070 hasAuthorship W3099690070A5001300397 @default.
• W3099690070 hasAuthorship W3099690070A5008969784 @default.
• W3099690070 hasAuthorship W3099690070A5013174582 @default.
• W3099690070 hasAuthorship W3099690070A5014129738 @default.
• W3099690070 hasAuthorship W3099690070A5026093243 @default.
• W3099690070 hasAuthorship W3099690070A5028047400 @default.
• W3099690070 hasAuthorship W3099690070A5034845901 @default.
• W3099690070 hasAuthorship W3099690070A5043675371 @default.
• W3099690070 hasAuthorship W3099690070A5051920004 @default.
• W3099690070 hasAuthorship W3099690070A5053058346 @default.
• W3099690070 hasAuthorship W3099690070A5060528631 @default.
• W3099690070 hasAuthorship W3099690070A5086182958 @default.
• W3099690070 hasConcept C108215921 @default.
• W3099690070 hasConcept C121608353 @default.
• W3099690070 hasConcept C126322002 @default.
• W3099690070 hasConcept C143998085 @default.
• W3099690070 hasConcept C150903083 @default.
• W3099690070 hasConcept C197934379 @default.
• W3099690070 hasConcept C203014093 @default.
• W3099690070 hasConcept C207001950 @default.
• W3099690070 hasConcept C25938499 @default.
• W3099690070 hasConcept C2776694085 @default.
• W3099690070 hasConcept C2777701055 @default.
• W3099690070 hasConcept C2778233292 @default.
• W3099690070 hasConcept C2781303535 @default.
• W3099690070 hasConcept C502942594 @default.
• W3099690070 hasConcept C71924100 @default.
• W3099690070 hasConcept C86803240 @default.
• W3099690070 hasConcept C8891405 @default.
• W3099690070 hasConcept C98274493 @default.
• W3099690070 hasConceptScore W3099690070C108215921 @default.
• W3099690070 hasConceptScore W3099690070C121608353 @default.
• W3099690070 hasConceptScore W3099690070C126322002 @default.
• W3099690070 hasConceptScore W3099690070C143998085 @default.
• W3099690070 hasConceptScore W3099690070C150903083 @default.
• W3099690070 hasConceptScore W3099690070C197934379 @default.
• W3099690070 hasConceptScore W3099690070C203014093 @default.
• W3099690070 hasConceptScore W3099690070C207001950 @default.
• W3099690070 hasConceptScore W3099690070C25938499 @default.
• W3099690070 hasConceptScore W3099690070C2776694085 @default.
• W3099690070 hasConceptScore W3099690070C2777701055 @default.
• W3099690070 hasConceptScore W3099690070C2778233292 @default.
• W3099690070 hasConceptScore W3099690070C2781303535 @default.
• W3099690070 hasConceptScore W3099690070C502942594 @default.
• W3099690070 hasConceptScore W3099690070C71924100 @default.
• W3099690070 hasConceptScore W3099690070C86803240 @default.
• W3099690070 hasConceptScore W3099690070C8891405 @default.
• W3099690070 hasConceptScore W3099690070C98274493 @default.
• W3099690070 hasLocation W30996900701 @default.
• W3099690070 hasOpenAccess W3099690070 @default.
• W3099690070 hasPrimaryLocation W30996900701 @default.
• W3099690070 hasRelatedWork W13154270 @default.
• W3099690070 hasRelatedWork W158596 @default.
• W3099690070 hasRelatedWork W19244877 @default.
• W3099690070 hasRelatedWork W2011212 @default.
• W3099690070 hasRelatedWork W20305632 @default.
• W3099690070 hasRelatedWork W2065971 @default.
• W3099690070 hasRelatedWork W2151330 @default.
• W3099690070 hasRelatedWork W7444607 @default.
• W3099690070 hasRelatedWork W7982055 @default.
• W3099690070 hasRelatedWork W9749177 @default.
• W3099690070 isParatext "false" @default.
• W3099690070 isRetracted "false" @default.
• W3099690070 magId "3099690070" @default.
• W3099690070 workType "article" @default.